RUA Life Sciences (GB:RUA)
LSE:RUA
Want to see GB:RUA full AI Analyst Report?
RUA Stock Chart & Stats
14.00 p
-0.50 p(-3.85%)
At close: 4:00 PM EST
14.00 p
-0.50 p(-3.85%)
Day’s Range― - ―
52-Week Range10.42 p - 26.80 p
Previous CloseN/A
Volume378.53K
Average Volume (3M)148.53K
Market Cap
£11.17M
Enterprise Value10.52M
Total Cash (Recent Filing)£3.25M
Total Debt (Recent Filing)£794.00K
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Jul 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding62,060,272
10 Day Avg. Volume90,619
30 Day Avg. Volume148,527
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.98
Price to Sales (P/S)1.57
P/FCF Ratio-23.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£7.10M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & High Gross MarginSustained top-line expansion alongside a ~69% gross margin indicates strong product-market fit and durable unit economics. High gross margins provide structural cushioning for R&D and SG&A as volumes grow, improving the path to eventual operating leverage and long-term profitability.
Conservative Balance Sheet / Low LeverageVery low leverage reduces refinancing and interest-rate risk, preserving financial optionality. A conservative capital structure supports continued investment in product development or capacity expansion without immediate pressure to cut growth, a durable strength over the medium term.
Specialised Medtech Manufacturing & Technology ServicesIntegrated capabilities in polymer/biomaterial device development and contract manufacturing create customer stickiness and technical barriers. These tailored services and IP-rich products support recurring revenue opportunities and durable competitive differentiation in medtech supply chains.
Bears Say
Persistent Negative Operating & Free Cash FlowOngoing cash burn means the business is not yet self-funding; continued negative operating and free cash flow increases reliance on external financing. This structural funding need can dilute shareholders or constrain strategic investments if losses persist over the next several quarters.
Lack Of Operating ProfitabilityDespite revenue scale-up, negative EBIT margins show the company has not converted sales into consistent operating profits. Structural improvements in cost base or pricing are required; without sustainable operating profitability, long-term returns and reinvestment capacity remain uncertain.
Limited Scale And Modest ReturnsA small employee base and modest equity mean limited internal capacity to scale rapidly and absorb setbacks. Negative ROE indicates capital is not yet generating returns, increasing vulnerability to operational shocks and making multi-quarter execution and growth delivery more challenging.
RUA Life Sciences News
RUA FAQ
What was RUA Life Sciences’s price range in the past 12 months?
RUA Life Sciences lowest share price was 10.42 p and its highest was 26.80 p in the past 12 months.
What is RUA Life Sciences’s market cap?
RUA Life Sciences’s market cap is £11.17M.
When is RUA Life Sciences’s upcoming earnings report date?
RUA Life Sciences’s upcoming earnings report date is Jul 13, 2026 which is in 39 days.
How were RUA Life Sciences’s earnings last quarter?
RUA Life Sciences released its earnings results on Jan 30, 2026. The company reported 0.008 p earnings per share for the quarter, beating the consensus estimate of N/A by 0.008 p.
Is RUA Life Sciences overvalued?
According to Wall Street analysts RUA Life Sciences’s price is currently Overvalued.
Does RUA Life Sciences pay dividends?
RUA Life Sciences does not currently pay dividends.
What is RUA Life Sciences’s EPS estimate?
RUA Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RUA Life Sciences have?
RUA Life Sciences has 62,060,272 shares outstanding.
What happened to RUA Life Sciences’s price movement after its last earnings report?
RUA Life Sciences reported an EPS of 0.008 p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -7.937%.
Which hedge fund is a major shareholder of RUA Life Sciences?
Currently, no hedge funds are holding shares in GB:RUA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RUA Life Sciences
RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.
Technical Analysis
Creo Medical
―
Genedrive
―
Inspiration Healthcare
―
OptiBiotix Health
―
Surgical Innovations
―
Options Prices
Currently, No data available
---